Laura Esfeller, Director of Marketing Services at San Manuel Band of Mission Indians, shared a post on X:
“Don’t forget: SWOG Cancer Research Network S2200 is still enrolling patients! Exciting study for a group of us in kidney cancer who don’t have a lot of clinical trial options: metastatic papillary RCC. The amazing is leading PAPMET2.”
Benjamin Maughan, Medical Oncologist at Johns Hopkins School of Medicine, shared this post adding:
“Lots to learn from this and other ongoing trials in papillary kidney cancer. S1500 and others show us that it’s possible — please consider this trial for all your patients with this disease.”
More posts featuring Laura Esfeller.